Novartis AG ADR is a drug manufacturers - general business based in the US. Novartis AG ADR shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $108.70 – a decrease of 4.89% over the previous week. Novartis AG ADR employs 75,883 staff and has a trailing 12-month revenue of around $53.2 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $108.70 |
|---|---|
| 52-week range | $92.72 - $116.72 |
| 50-day moving average | $110.34 |
| 200-day moving average | $108.98 |
| Wall St. target price | $112.37 |
| PE ratio | 17.9138 |
| Dividend yield | $3.862 (3.49%) |
| Earnings per share (TTM) | $6.38 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $110.13 from 2025-05-08
| 1 week (2025-05-02) | -3.64% |
|---|---|
| 1 month (2025-04-10) | 6.51% |
| 3 months (2025-02-10) | 3.07% |
| 6 months (2024-11-08) | 3.46% |
| 1 year (2024-05-10) | 7.86% |
|---|---|
| 2 years (2023-05-10) | 20.79% |
| 3 years (2022-05-10) | 55.16% |
| 5 years (2020-05-08) | 67.86% |
Valuing Novartis AG ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis AG ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis AG ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Novartis AG ADR shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novartis AG ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.364. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis AG ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis AG ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $22.1 billion.
The EBITDA is a measure of a Novartis AG ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $53.2 billion |
|---|---|
| Operating margin TTM | 35.4% |
| Gross profit TTM | $40.3 billion |
| Return on assets TTM | 11.42% |
| Return on equity TTM | 32.89% |
| Profit margin | 24.16% |
| Book value | $19.58 |
| Market Capitalization | $225.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 66.46% of net profits
Recently Novartis AG ADR has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis AG ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Novartis AG ADR's case, that would currently equate to about $3.862 per share.
Novartis AG ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novartis AG ADR's most recent dividend payout was on 24 April 2025. The latest dividend was paid out to all shareholders who bought their shares by 11 March 2025 (the "ex-dividend date").
Novartis AG ADR's shares were split on a 1116:1000 basis on 8 April 2019 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis AG ADR shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis AG ADR shares which in turn could have impacted Novartis AG ADR's share price.
Over the last 12 months, Novartis AG ADR's shares have ranged in value from as little as $92.7237 up to $116.7179. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis AG ADR's is 0.545. This would suggest that Novartis AG ADR's shares are less volatile than average (for this exchange).
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.